LivaNova (NASDAQ:LIVN) Issues FY25 Earnings Guidance

LivaNova (NASDAQ:LIVN) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided EPS guidance of $3.65-3.75 for the period, compared to the consensus EPS estimate of $3.66. The company issued revenue guidance of ~$1.316-1.329 billion, compared to the consensus revenue estimate of $1.33 billion. LivaNova also updated its FY 2025 guidance to 3.650-3.750 EPS.

LivaNova Trading Down 0.0 %

Shares of LivaNova stock traded down $0.02 during trading on Wednesday, hitting $41.68. The stock had a trading volume of 250,823 shares, compared to its average volume of 530,955. The firm’s fifty day simple moving average is $47.78 and its 200-day simple moving average is $49.62. The stock has a market cap of $2.26 billion, a PE ratio of 99.13 and a beta of 1.00. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova has a 12 month low of $40.37 and a 12 month high of $64.47.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on LIVN shares. Robert W. Baird raised their target price on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Stifel Nicolaus decreased their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday. Mizuho decreased their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday. Finally, StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday, February 14th. Two analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $65.33.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the sale, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.27% of the stock is owned by insiders.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.